



07-27-06

Attorney's Docket No.: 18852-002002/5202B

1Pw\$

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen R. Hanson  
Serial No. : 10/603,401  
Filed : June 25, 2003  
Cust. No. : 20985  
Title : METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS

Art Unit : 1615  
Examiner : Eric E. Silverman  
Conf. No. : 3459

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page), cited references and a replacement Form PTO-1449 (4 pages) originally submitted with the Information Disclosure Statement mailed June 25, 2003 for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is after receipt of a first Office Action on the Merits of the above-captioned application, the filing fee of \$180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1050, as stated below:



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 18852-002002  
Address all correspondence to:  
Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 740121981 US  
Date of Deposit July 25, 2006  
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman



Attorney's Docket No.: 18852-002002/5202B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen R. Hanson  
Serial No. : 10/603,401  
Filed : June 25, 2003  
Cust. No. : 20985  
Title : METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS

Art Unit : 1615  
Examiner : Thurman K. Page  
Conf. No. : 3459

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN  
ACCORDANCE WITH 37 C.F.R. §§1.97-1.98**

Dear Sir:

Because this Supplemental Information Disclosure Statement is after receipt of a first Office Action on the Merits of the above-captioned application, the filing fee of \$180 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited references are provided herewith in connection with the above-captioned application.

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed item is necessary.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 740121981 US  
Date of Deposit July 25, 2006  
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

07/28/2006 RMEBRAHT 00000027 10603401

01 FC:1806

180.00 DP

Applicant : Stephen R. Hanson  
Serial No. : 10/603,401  
Filed : June 25, 2003  
Page : 2 of 2

Attorney's Docket No.: 18852-002002/5202B

Also provide is a replacement copy of a Form PTO-1449 (4 pages) that was previously submitted with the Information Disclosure Statement mailed on June 25, 2003. In the Office Action mailed January 20, 2006, references B1 through C63 listed on the Form PTO-1449 were not initialed because the Examiner noted that copies of the references were not provided. Copies of references B1 – C49, C51, C52 and C55 – C63 were not provided as they were been previously provided in connection with U.S. Serial No. 09/666,223 (now US Patent No. 6,585,995), which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120. Items C50, C53 and C54 were newly cited in this application. Item C53 was submitted with the Information Disclosure Statement mailed on September 12, 2005 and is of record in the instant application. Copies of C50 and C54 are provided herewith. Thus, copies of these references are now available for the Examiner to consider. A clean, replacement copy of the Form PTO-1449 is provided for the Examiner to initial.


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references or information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g and h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and make them of record in the file history of the above-captioned application.

Respectfully submitted,

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 18852-002002/5202B  
Address all correspondence to:  
Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com

Sheet 1 of 1Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
18852-002002/5202BApplication No.  
10/603,401**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Stephen R. HansonFiling Date  
June 25, 2003Group Art Unit  
1615**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2002/0099013	07/25/2002	Piccariello et al.			
	AB	2006/0030574	02/09/2006	Franklin, Richard			
	AC	2006/0052601	03/09/2006	Franklin, Richard			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AD	2002/058676	08/01/2002	PCT				
	AE	2002/08228	01/31/2002	PCT				
	AF	2004/000280	12/31/2003	PCT				
	AG	2004/064841	08/05/2004	PCT				
	AH	2006/017822	02/16/2006	PCT				
	AI	2006/017823	02/16/2006	PCT				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
		none

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

APPLICATION NO.: Not yet assigned

ATTY. DOCKET NO.: H00646.70001.US

FILING DATE: June 25, 2003

APPLICANT: Stephen R. Hanson

GROUP ART UNIT: Not yet assigned

EXAMINER: Not yet assigned

Sheet 1 of 4

**U.S. PATENT DOCUMENTS**

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		
	*A1	3,932,407		Beverung, Jr., et al.	01/13/76
	*A2	3,978,213		Lapinet, et al.	08/31/76
	*A3	4,088,753		Parmer	05/09/78
	*A4	4,146,718		Jenks, et al.	03/27/79
	*A5	4,206,214		Harker, et al.	06/03/80
	*A6	4,208,521		Crenshaw, et al.	06/17/80
	*A7	4,357,330		Fleming, Jr., et al.	02/02/82
	*A8	4,393,063		Moncada	07/12/83
	*A9	4,404,212		Moncada	09/13/83
	*A10	4,406,904		Welle, et al.	09/27/83
	*A11	4,432,980		Fleming, Jr., et al.	02/21/84
	*A12	4,436,934		Larock	03/13/84
	*A13	4,444,777		Fleming, Jr., et al.	04/24/84
	*A14	4,568,676		Smith	02/04/86
	*A15	4,743,445		Delwiche, et al.	05/10/88
	*A16	4,847,276		Yarrington	07/11/89
	*A17	5,185,323		Gewirtz	02/09/93
	*A18	5,306,709		Gewirtz	04/26/94
	*A19	5,391,557		Cullinan, et al.	02/21/95
	*A20	5,391,737		Reiter, et al.	02/21/95
	*A21	5,440,020		Coller	08/08/95
	*A22	5,472,944		Gewirtz, et al.	12/05/95
	*A23	5,620,960		Arnold, et al.	04/15/97
	*A24	5,789,539		Daly, et al.	08/04/98
	*A25	5,801,245		Lang	09/01/98
	*A26	6,008,232		Lakshmanan	12/28/99
	*A27	6,043,260		Chen, et al.	03/28/00
	*A28	6,103,740		Lakshmanan	08/15/00
	*A29	6,110,471		Conti, et al.	08/29/00
	*A30	6,156,753		Doherty, Jr., et al.	12/05/00
	*A31	6,287,599	B1	Burnside et al.	09/11/01
	*A32	RE 31,617		Beverung, Jr., et al.	06/26/84
	A33	6,376,242		Hanson	04/23/02

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*B1	EP	0 260 527	A		03/23/88	Abstract
	*B2	EP	0 778 258			06/97	
	*B3	EP	0 994 114			04/00	

	*B4	EP	0 514 917			11/25/92	
	*B5	EP	0 904 783			03/99	
	*B6	HU	206 496	B		11/30/92	Abstract
	*B7	PCT	WO99/08524			02/99	
	*B8	PCT	WO99/08525			02/99	
	*B9	PCT	WO99/20223			04/99	
	*B10	PCT	WO93/23426			25/11/93	Abstract
	*B11	PCT	WO99/34792			07/15/99	
	*B12	UK	GB2,256,195			12/92	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*C1	Al-Jibouri, L.M. and Najim, R.A., "Effect of dipyridamole on blood glucose and liver cyclic AMP levels and platelet count during endotoxaemia in mice", <i>Clin. Exp. Pharmacol. Physiol.</i> , 15(7):527-32 (1988) <b>ABSTRACT</b>	
	*C2	Andes, et al., "Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers", <i>Thromb Haemost.</i> , 52(3):325-8 (1984)	
	*C3	Balan, K.K and Critchley, M., "Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32—a 15 year review", <i>Br. J. Radiol.</i> , 70(839):1169-73 (1997) <b>ABSTRACT</b>	
	*C4	Balduini, et al., "Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders", <i>Haematologica</i> , 77(1):40-3 (1992) <b>ABSTRACT</b>	
	*C5	Barnathan, et al., "Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty", <i>Circulation</i> , 76(1):125-134 (1987)	
	*C6	Bellucci, et al., "Positive and negative regulation of megakaryocytopoiesis", <i>C.R. Seances Soc. Biol. Fil.</i> , 190(5-6):515-32 (1996) <b>ABSTRACT</b>	
	*C7	Bunn, H.F., "Pathophysiology of the anemias", <i>Harrison's Principles of Internal Medicine: Hematology and Oncology</i> , 1514, 1566-67 New York, McGraw-Hill, (1991)	
	*C8	Cazenave, J.P. and Gachet, C., "Anti-platelet drugs: do they affect megakaryocytes?", <i>Baillieres Clin Haematol</i> , 10(1):163-80 (1997)	
	*C9	Chen, et al., "Thrombospondin, a negative modulator of megakaryocytopoiesis", <i>J. Lab. Clin. Med.</i> , 129(2):231-8 (1997) <b>ABSTRACT</b>	
	*C10	Cortelazzo, et al., "Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis", <i>N. Engl. J. Med.</i> , 332(17):1132-6 (1995) <b>ABSTRACT</b>	
	*C11	Dale, et al., "Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand", <i>Blood</i> , 90(9):3456-3461 (1997)	
	*C12	Davies, et al., "Adverse events reported by postmenopausal women in controlled trials with raloxifene", <i>Obstetrics &amp; Gynecology</i> , 93(4):558-565 (1999)	
	*C13	De Serres, et al., "Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man", <i>Stem Cells</i> , 17:203-209 (1999)	
	*C14	Deng, et al., "A monoclonal antibody cross-reactive with human platelets, megakaryocytes, and common acute lymphocytic leukemia cells", <i>Blood</i> , 61(4):759-764 (1983)	
	*C15	Gaver, et al., "Disposition of anagrelide, an inhibitor of platelet aggregation", <i>Clin. Pharmacol. Ther.</i> , 29(3):381-6 (1981) <b>ABSTRACT</b>	
	*C16	Gewirtz, et al., "Cell-mediated suppression of megakaryocytopoiesis in acquired megakaryocytic thrombocytopenic purpura", <i>Blood</i> , 68(3):619-26 (1986) <b>ABSTRACT</b>	
	*C17	Glushkov, et al., "Changes in hemostatic system indices during hemosorption in healthy dogs", <i>Biull Eksp Biol. Med.</i> , 94(7):95-8 (1982) <b>ABSTRACT</b>	
	*C18	Goldberg, et al., "Thrombocytotic suppression of megakaryocyte production from stem cells", <i>Blood</i> , 49(1):59-69 (1977) <b>ABSTRACT</b>	
	*C19	Gugliotta, et al., "In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia", <i>Br. J. Haematol.</i> , 71(2):177-81 (1989) <b>ABSTRACT</b>	
	*C20	Herron, et al., "Inhibition of megakaryocytic colonies <i>in vitro</i> by anagrelide", <i>Clin. Res.</i> , 34(2):459A (1986) <b>ABSTRACT</b>	
	*C21	Hung, et al., "Focused antithrombotic therapy: novel anti-platelet salicylates with reduced	

		ulcerogenic potential and higher first-pass detoxification than aspirin in rats", <i>J. Lab. Clin. Med.</i> , 132(6):469-77 (1998) <b>ABSTRACT</b>		
	*C22	Jones, et al., "Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide", <i>J. Med. Chem.</i> , 30(2):295-303 (1987) <b>ABSTRACT</b>		
	*C23	Lecomte-Raclet, et al., "New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides", <i>Blood</i> , 91(8):2772-80 (1998) <b>ABSTRACT</b>		
	*C24	Ludwig, et al., "Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders", <i>Cancer Immunol. Immunother.</i> , 25(3):266-73 (1987) <b>ABSTRACT</b>		
	*C25	Mazur, et al., "Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans", <i>Blood</i> , 79(8):1931-1937 (1992)		
	*C26	Mazzucconi, et al., "Pipobroman therapy of essential thrombocythemia", <i>Scand J. Haematol.</i> , 37(4):306-9 (1986) <b>ABSTRACT</b>		
	*C27	Mazzucconi, et al., "Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results", <i>Haematologica</i> , 77(4):315-7 (1992) <b>ABSTRACT</b>		
	*C28	McCune, et al., "Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations", <i>Pharmacotherapy</i> , 17(4):822-6 (1997) <b>ABSTRACT</b>		
	*C29	Meanwell, et al., "Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains", <i>J. Med. Chem.</i> , 35(14):2672-87 (1992) <b>ABSTRACT</b>		
	*C30	Nagae, S. and Hori, Y., "Immune thrombocytopenia due to Tranilast (Rizaben): detection of drug-dependent platelet-associated IgG", <i>J. Dermatol.</i> , 25(11):706-9 (1998)		
	*C31	Negrev, et al., "Influence of nonselective beta-adrenergic impacts on the effects of thrombopoietin in mice", <i>Acta Physiologica et Pharmacologica Bulgaria</i> , 13:1:35-39 (1987)		
	*C32	Ramires, et al., "Effect of ticlopidine and dipyridamole on platelet aggregation and count in patients with chronic stable angina pectoris", <i>Arq Bras. Cardiol.</i> , 56(4):323-7 (1991) <b>ABSTRACT</b>		
	*C33	Robak, T. et al., "Anagrelide—new antiplatelet drug", <i>Acta Haematol Pol.</i> , 25(4):309-15 (1994) <b>ABSTRACT</b>		
	*C34	Sato, et al., "Multivariate analysis of risk factors for thrombus formation in University of Tokyo ventricular assist device", <i>J. Thorac. Cardiovasc. Surg.</i> , 106:520-7 (1993)		
	*C35	Scott, et al., "Local delivery of an antithrombin inhibits platelet-dependent thrombosis", <i>Circulation</i> , 90(4):1951-1955 (1994)		
	*C36	Seiler, et al., "Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca <sup>++</sup> fluxes", <i>J. Pharmacol Exp. Ther.</i> , 243(2):767-74 (1987) <b>ABSTRACT</b>		
	*C37	Shinagawa, et al., "Allopurinol induced pancytopenia in a patient with myeloproliferative disorder", <i>Rinsho Ketsueki</i> , 38(1):64-71 (1997) <b>ABSTRACT</b>		
	*C38	Smith, J.B. "Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase", <i>Thromb Res.</i> , 15:28(4):477-85 (1982) <b>ABSTRACT</b>		
	*C39	Solberg, et al., "The effects of anagrelide on human megakaryocytopoiesis", <i>Br. J. Haematol.</i> , 99(1):174-80 (1997) <b>ABSTRACT</b>		
	*C40	Thaulow, et al., "Blood platelet count and function are related to total and cardiovascular death in apparently healthy men", <i>Circulation</i> 84(2):613-617 (1991)		
	*C41	Trowbridge, et al., "Platelet production in myocardial infarction and sudden cardiac death", <i>Thromb. Haemost.</i> , 52(2):167-171 (1984)		
	*C42	Van de Pette, "Primary thrombocythaemia treated with busulphan", <i>Br. J. Haematol.</i> , 62(2):229-37 (1986) <b>ABSTRACT</b>		
	*C43	van der Loo, et al., "Megakaryocytes and platelets in vascular disease", <i>Bailliere's Clinical Haematology</i> , 10(1):109-123 (1997)		
	*C44	Venuti, et al., "Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline", <i>J. Med. Chem.</i> , 31(11):2136-45 (1988) <b>ABSTRACT</b>		
	*C45	Wada, et al., "Characterization of the truncated thrombopoietin variants", <i>Biochem. Biophys. Res. Comm.</i> , 213(3):1091-1098 (1995)		
	*C46	Wadenvik, et al., "The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia", <i>Blood</i> , 77(10):2103-8 (1991) <b>ABSTRACT</b>		
	*C47	Wilhelmsen, L., "Thrombocytes and coronary heart disease", <i>Circulation</i> 84(2):936-938 (1991)		
	*C48	Yataganas, et al., "alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis", <i>Eur. J. Cancer</i> , 27 Suppl 4:S69-71 (1991) <b>ABSTRACT</b>		
	*C49	Yeager, et al., "Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels", <i>J. Cell.</i>		

		<i>Physiol.</i> , 112(2):222-8 (1982) ABSTRACT		
	*C50	Harker, et al., "Regulation of Platelet Production and Function by Megakaryocyte Growth and Development Factor in Nonhuman Primates", <i>Blood</i> , Vol. 87, No. 5, pp. 1833-1844, (1996)		
	*C51	Harker, "Platelets in Thrombotic Disorders: Quantitative and Qualitative Platelet Disorders Predisposing to Arterial Thrombosis", <i>Seminars in Hematology</i> , Vol. 35, No. 3, pp. 241-252, (1998)		
	*C52	van der Loo, et al. "A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes", <i>Arterioscler Thromb Vasc Biol.</i> , Vol. 19, pp. 672-679 (1999)		
	*C53	Broudy, et al., "Thrombopoietin Stimulates Colony-Forming Unit-Megakaryocyte Proliferation and Megakaryocyte Maturation Independently of Cytokines that Signal through the gp130 Receptor Subunit," <i>Blood</i> , Vol. 8, No. 6, pp. 2026-2032 (1996)		
	*C54	Luoh, et al., "Role of the Distal Half of the CMPL Intracellular Domain on Control of Platelet Production by Thrombopoietin in Vivo," <i>Mol. Cell. Biol.</i> , Vol. 20, No. 2, pp. 507-515 (2000)		
	*C55	Landolfi, et al., "Aspirin in Polycythemia Vera and Essential Thrombocythemia: Current facts and Perspectives", <i>Leukemia and Lymphoma</i> , 1996, Vol. 22, Suppl. 1, pp. 83-86		
	*C56	Lane, et al., "Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation," <i>Experimental Hematology</i> , 2001, Vol. 29, pp. 1417-1424		
	*C57	Harker, "Platelets in Thrombotic Disorders: Quantitative and Qualitative Platelet Disorders Predisposing to Arterial Thrombosis", <i>Seminars in Hematology</i> , Vol. 35, No. 3, pp. 241-252 (1998)		
	*C58	van der Loo, et al., "A Role for Changes in Platelet Production in the Cause of Acute Coronary Syndromes", <i>Arterioscler Thromb Vasc Biol.</i> , Vol. 19, pp. 672-679 (1999)		
	*C60	Hennekens, "Update on aspirin in the treatment and prevention of cardiovascular disease" <i>Am. Heart J.</i> , 137 (4 Pt2):S9-S13 (1999) Abstract only		
	*C61	Tang, et al. "Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3',5'-adenosine monophosphate phosphodiesterase", <i>J. Lab.Clin. Med.</i> , 95(2):241-57 (1980)		
	*C62	Fleming, et al., "A Potent New Inhibitor of Platelet Aggregation and Experimental Thrombosis, Anagrelide (BL-4162A)", <i>Throm. Res.</i> , 15(3-4):373-88 (1979)		
	*C63	Merck Research Laboratories, N. J., "the merck manual", 1999, p. 918, column 2, paragraph 4		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/666,223, filed September 21, 2000, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]